Skip to search formSkip to main contentSkip to account menu

gp96-Ig fusion protein-expressing non-small cell lung cancer cell vaccine

Known as: gp96-Ig fusion protein vaccine, HS110, Viagenpumatucel-L 
A proprietary, allogeneic tumor cell vaccine expressing a recombinant secretory form of the heat shock protein gp96 fusion (gp96-Ig) with potential… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
9546Background: Viagenpumatucel-L (HS-110) is an allogeneic cellular vaccine derived from a human lung adenocarcinoma cell line… 
2019
2019
9109 Background: Viagenpumatucel-L (HS-110) is an allogeneic cellular vaccine derived from a human lung adenocarcinoma cell line… 
2019
2019
Our technology is focused on developing a next generation cellular vaccine platform – referred to as ComPACT (COMbination Pan… 
2019
2019
101 Background: Viagenpumatucel-L (HS-110) is an allogeneic cellular vaccine derived from a human lung adenocarcinoma (AD) cell… 
2016
2016
TPS9102Background: Viagenpumatucel-L (HS-110) is an allogeneic whole-cell vaccine, selected for high expression of adenocarcinoma… 
2015
2015
3077 Background: Viagenpumatucel-L (HS-110), consists of an allogeneic NSCLC cell line, selected for high expression of a series… 
2014
2014
Meeting abstracts Viagenpumatucel-L (HS-110) is an allogeneic cell-based therapeutic cancer vaccine for the treatment of… 
Highly Cited
2000
Highly Cited
2000
A major quantitative trait locus (QTL) controlling response to photoperiod, Hd1, was identified by means of a map-based cloning…